CyPath Lung
@cypathlung.bsky.social
Noninvasive Early Lung Cancer Detection
bioAffinity Technologies observe #VeteransDay by reaffirming our commitment to helping Veterans live longer and healthier lives through early detection of lung cancer. CyPath® Lung is now available to Veterans through the VA health system.
November 11, 2025 at 6:41 PM
bioAffinity Technologies observe #VeteransDay by reaffirming our commitment to helping Veterans live longer and healthier lives through early detection of lung cancer. CyPath® Lung is now available to Veterans through the VA health system.
November is #LungCancerAwarenessMonth.
Lung cancer is the leading cause of cancer death worldwide, and anyone with lungs can be at risk.
Awareness and early detection save lives, we're proud to advance science and education that help make that possible.
Lung cancer is the leading cause of cancer death worldwide, and anyone with lungs can be at risk.
Awareness and early detection save lives, we're proud to advance science and education that help make that possible.
November 6, 2025 at 11:20 PM
November is #LungCancerAwarenessMonth.
Lung cancer is the leading cause of cancer death worldwide, and anyone with lungs can be at risk.
Awareness and early detection save lives, we're proud to advance science and education that help make that possible.
Lung cancer is the leading cause of cancer death worldwide, and anyone with lungs can be at risk.
Awareness and early detection save lives, we're proud to advance science and education that help make that possible.
This #LungCancerAwarenessMonth, bioAffinity Tech ($BIAF) reports accelerating growth in sales of CyPath® Lung, with October test volume up 111% over 2025’s average.
Early detection saves lives. Learn more: bit.ly/4qL5v6h
Early detection saves lives. Learn more: bit.ly/4qL5v6h
November 5, 2025 at 11:02 PM
This #LungCancerAwarenessMonth, bioAffinity Tech ($BIAF) reports accelerating growth in sales of CyPath® Lung, with October test volume up 111% over 2025’s average.
Early detection saves lives. Learn more: bit.ly/4qL5v6h
Early detection saves lives. Learn more: bit.ly/4qL5v6h
Day 2 at #CHEST2025! Great conversations with clinicians & researchers advancing noninvasive lung diagnostics.
Our team at Booth 2242 is sharing how #CyPathLung uses flow cytometry + #AI to support earlier, more accurate detection of lung cancer.
#bioAffinityTechnologies #LungHealth #Diagnostics
Our team at Booth 2242 is sharing how #CyPathLung uses flow cytometry + #AI to support earlier, more accurate detection of lung cancer.
#bioAffinityTechnologies #LungHealth #Diagnostics
October 21, 2025 at 8:54 PM
Day 2 at #CHEST2025! Great conversations with clinicians & researchers advancing noninvasive lung diagnostics.
Our team at Booth 2242 is sharing how #CyPathLung uses flow cytometry + #AI to support earlier, more accurate detection of lung cancer.
#bioAffinityTechnologies #LungHealth #Diagnostics
Our team at Booth 2242 is sharing how #CyPathLung uses flow cytometry + #AI to support earlier, more accurate detection of lung cancer.
#bioAffinityTechnologies #LungHealth #Diagnostics
Big week at #CHEST2025!
Dr. Rossella Titone shares new research showing how CyPath® Lung stays accurate from sample to result. Proud of Dr. Titone, Dr. Downie & Dr. Elzi for representing!
Dr. Rossella Titone shares new research showing how CyPath® Lung stays accurate from sample to result. Proud of Dr. Titone, Dr. Downie & Dr. Elzi for representing!
October 20, 2025 at 8:11 PM
Big week at #CHEST2025!
Dr. Rossella Titone shares new research showing how CyPath® Lung stays accurate from sample to result. Proud of Dr. Titone, Dr. Downie & Dr. Elzi for representing!
Dr. Rossella Titone shares new research showing how CyPath® Lung stays accurate from sample to result. Proud of Dr. Titone, Dr. Downie & Dr. Elzi for representing!
October 20, 2025 at 3:34 PM
AI is revolutionizing cancer detection. The USPTO plans to grant bioAffinity Technologies a patent for our AI-powered flow cytometry platform that detects lung cancer with precision and consistency. Learn more: bit.ly/42N8CAq
#CyPathLung #cancerdiagnostics #patent #AI
#CyPathLung #cancerdiagnostics #patent #AI
bit.ly
October 17, 2025 at 3:24 PM
AI is revolutionizing cancer detection. The USPTO plans to grant bioAffinity Technologies a patent for our AI-powered flow cytometry platform that detects lung cancer with precision and consistency. Learn more: bit.ly/42N8CAq
#CyPathLung #cancerdiagnostics #patent #AI
#CyPathLung #cancerdiagnostics #patent #AI
Reposted by CyPath Lung
The ATS and CAPC are proud to introduce a new collaborative series of seven modules on ATS Ed+ for clinicians treating patients with serious illnesses. Earn CME! #pallipulm @anandiyermd.bsky.social @donsullivan.bsky.social @pallipulm.bsky.social
Learn more: atsedplus.thoracic.org/capc/palliat...
Learn more: atsedplus.thoracic.org/capc/palliat...
September 30, 2025 at 4:30 PM
The ATS and CAPC are proud to introduce a new collaborative series of seven modules on ATS Ed+ for clinicians treating patients with serious illnesses. Earn CME! #pallipulm @anandiyermd.bsky.social @donsullivan.bsky.social @pallipulm.bsky.social
Learn more: atsedplus.thoracic.org/capc/palliat...
Learn more: atsedplus.thoracic.org/capc/palliat...
On World Lung Day, we honor patients and families and look forward with hope. CyPath® Lung is committed to earlier detection, so every patient can have more time and more moments.
#WorldLungDay #LungHealth #EarlyDetection #CyPathLung
#WorldLungDay #LungHealth #EarlyDetection #CyPathLung
September 25, 2025 at 8:02 PM
On World Lung Day, we honor patients and families and look forward with hope. CyPath® Lung is committed to earlier detection, so every patient can have more time and more moments.
#WorldLungDay #LungHealth #EarlyDetection #CyPathLung
#WorldLungDay #LungHealth #EarlyDetection #CyPathLung
Indeterminate lung nodules don’t have to mean uncertainty.
CyPath® Lung is a noninvasive sputum test that uses flow cytometry to deliver:
✅92% sensitivity
✅87% specificity
Fewer unnecessary procedures.
Clearer, faster answers.
#LungCancer #EarlyDetection #CyPathLung
CyPath® Lung is a noninvasive sputum test that uses flow cytometry to deliver:
✅92% sensitivity
✅87% specificity
Fewer unnecessary procedures.
Clearer, faster answers.
#LungCancer #EarlyDetection #CyPathLung
September 23, 2025 at 8:33 PM
Indeterminate lung nodules don’t have to mean uncertainty.
CyPath® Lung is a noninvasive sputum test that uses flow cytometry to deliver:
✅92% sensitivity
✅87% specificity
Fewer unnecessary procedures.
Clearer, faster answers.
#LungCancer #EarlyDetection #CyPathLung
CyPath® Lung is a noninvasive sputum test that uses flow cytometry to deliver:
✅92% sensitivity
✅87% specificity
Fewer unnecessary procedures.
Clearer, faster answers.
#LungCancer #EarlyDetection #CyPathLung
CyPath® Lung helped detect a malignancy in ground-glass nodules in a 66-year-old patient with a smoking history, supporting earlier detection and better care.
Watch Dr. Guda’s interview: www.cypathlung.com
#LungCancer #EarlyDetection #CyPathLung #PhysicainHighlights
Watch Dr. Guda’s interview: www.cypathlung.com
#LungCancer #EarlyDetection #CyPathLung #PhysicainHighlights
September 11, 2025 at 3:07 PM
CyPath® Lung helped detect a malignancy in ground-glass nodules in a 66-year-old patient with a smoking history, supporting earlier detection and better care.
Watch Dr. Guda’s interview: www.cypathlung.com
#LungCancer #EarlyDetection #CyPathLung #PhysicainHighlights
Watch Dr. Guda’s interview: www.cypathlung.com
#LungCancer #EarlyDetection #CyPathLung #PhysicainHighlights
Ground-glass nodules often mean years of “watchful waiting.” In a new case, CyPath® Lung delivered actionable results that led to timely lung cancer diagnosis and treatment.
Read more: bit.ly/3JNK181
#LungCancer #Diagnostics #CyPathLung
Read more: bit.ly/3JNK181
#LungCancer #Diagnostics #CyPathLung
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules - bioAffinity
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO, TX – September 9, 2025 ...
bit.ly
September 9, 2025 at 4:51 PM
Ground-glass nodules often mean years of “watchful waiting.” In a new case, CyPath® Lung delivered actionable results that led to timely lung cancer diagnosis and treatment.
Read more: bit.ly/3JNK181
#LungCancer #Diagnostics #CyPathLung
Read more: bit.ly/3JNK181
#LungCancer #Diagnostics #CyPathLung
We are honored to be featured in U.S. Medicine. New issue includes a story on the economic impact of our #CyPathLung test for #lungcancer.
See our press release at bit.ly/47tdq12
See the US Medicine story at bit.ly/41XHLRR
#innovation #pulmonology #veterans
See our press release at bit.ly/47tdq12
See the US Medicine story at bit.ly/41XHLRR
#innovation #pulmonology #veterans
September 3, 2025 at 9:22 PM
We are honored to be featured in U.S. Medicine. New issue includes a story on the economic impact of our #CyPathLung test for #lungcancer.
See our press release at bit.ly/47tdq12
See the US Medicine story at bit.ly/41XHLRR
#innovation #pulmonology #veterans
See our press release at bit.ly/47tdq12
See the US Medicine story at bit.ly/41XHLRR
#innovation #pulmonology #veterans
Proud to see CyPath® Lung featured in U.S. Medicine’s August pulmonary issue.
Our noninvasive test can help veterans, 3x more likely to qualify for lung cancer screening, by improving detection, reducing unnecessary follow-ups & ⬇️costs.
📖 bit.ly/4mKrTKO
#LungCancer #VeteransHealth #CyPathLung
Our noninvasive test can help veterans, 3x more likely to qualify for lung cancer screening, by improving detection, reducing unnecessary follow-ups & ⬇️costs.
📖 bit.ly/4mKrTKO
#LungCancer #VeteransHealth #CyPathLung
New Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA - U.S. Medicine
Lung cancer is the leading cause of cancer deaths in the United States. Early detection is vital, especially for veterans, who face a disproportionately high risk of lung cancer due to higher rates of...
bit.ly
August 29, 2025 at 5:51 PM
Proud to see CyPath® Lung featured in U.S. Medicine’s August pulmonary issue.
Our noninvasive test can help veterans, 3x more likely to qualify for lung cancer screening, by improving detection, reducing unnecessary follow-ups & ⬇️costs.
📖 bit.ly/4mKrTKO
#LungCancer #VeteransHealth #CyPathLung
Our noninvasive test can help veterans, 3x more likely to qualify for lung cancer screening, by improving detection, reducing unnecessary follow-ups & ⬇️costs.
📖 bit.ly/4mKrTKO
#LungCancer #VeteransHealth #CyPathLung
Indeterminate lung nodules can be difficult to assess by CT or PET imaging. CyPath® Lung detects cancer in nodules <20mm with 92% sensitivity & 87% specificity which helps physicians catch malignancy earlier for better patient outcomes. bit.ly/IsraelGarcia
#CyPathLung #LungCancer #EarlyDetection
#CyPathLung #LungCancer #EarlyDetection
August 28, 2025 at 10:36 PM
Indeterminate lung nodules can be difficult to assess by CT or PET imaging. CyPath® Lung detects cancer in nodules <20mm with 92% sensitivity & 87% specificity which helps physicians catch malignancy earlier for better patient outcomes. bit.ly/IsraelGarcia
#CyPathLung #LungCancer #EarlyDetection
#CyPathLung #LungCancer #EarlyDetection
Wrapped up #AABIP2025 sharing how CyPath® Lung helps detect lung cancer early, when treatment is most effective.
Grateful for the conversations, collaborations & commitment to advancing lung health.
#LungCancer #EarlyDetection #CyPathLung #PatientCare
Grateful for the conversations, collaborations & commitment to advancing lung health.
#LungCancer #EarlyDetection #CyPathLung #PatientCare
August 18, 2025 at 9:49 PM
Wrapped up #AABIP2025 sharing how CyPath® Lung helps detect lung cancer early, when treatment is most effective.
Grateful for the conversations, collaborations & commitment to advancing lung health.
#LungCancer #EarlyDetection #CyPathLung #PatientCare
Grateful for the conversations, collaborations & commitment to advancing lung health.
#LungCancer #EarlyDetection #CyPathLung #PatientCare
Looking forward to connecting at AABIP 2025 Conference 8/14. Visit Booth 44 to learn how physicians use CyPath® Lung as a noninvasive diagnostic tool to support early detection of lung cancer and improve patient care.
#CyPathLung #LungCancer #EarlyDetection #AABIP2025 #PatientCare
#CyPathLung #LungCancer #EarlyDetection #AABIP2025 #PatientCare
August 13, 2025 at 2:41 PM
Looking forward to connecting at AABIP 2025 Conference 8/14. Visit Booth 44 to learn how physicians use CyPath® Lung as a noninvasive diagnostic tool to support early detection of lung cancer and improve patient care.
#CyPathLung #LungCancer #EarlyDetection #AABIP2025 #PatientCare
#CyPathLung #LungCancer #EarlyDetection #AABIP2025 #PatientCare
When a CyPath® Lung sample delay arose, our team jumped into action, ensuring safe, timely delivery to the lab. When patient care is at the heart of our team, it can’t skip a beat. ❤️
#CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare
#CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare
August 12, 2025 at 4:44 PM
When a CyPath® Lung sample delay arose, our team jumped into action, ensuring safe, timely delivery to the lab. When patient care is at the heart of our team, it can’t skip a beat. ❤️
#CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare
#CyPathLung #LungCancer #PrecisionPathology #Teamwork #PatientCare
Only 2 days until AABIP! Visit us at Booth 44 to hear how CyPath® Lung is helping physicians detect lung cancer early, noninvasively, and with accuracy you can trust.
We’ll see you there!
#CyPathLung #LungCancer #EarlyDetection #AABIP
We’ll see you there!
#CyPathLung #LungCancer #EarlyDetection #AABIP
August 11, 2025 at 7:15 PM
Only 2 days until AABIP! Visit us at Booth 44 to hear how CyPath® Lung is helping physicians detect lung cancer early, noninvasively, and with accuracy you can trust.
We’ll see you there!
#CyPathLung #LungCancer #EarlyDetection #AABIP
We’ll see you there!
#CyPathLung #LungCancer #EarlyDetection #AABIP
With something as essential as breath, every moment matters.
Early detection saves lives. Let’s keep pushing for awareness and action.
#WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung
Early detection saves lives. Let’s keep pushing for awareness and action.
#WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung
August 1, 2025 at 7:47 PM
With something as essential as breath, every moment matters.
Early detection saves lives. Let’s keep pushing for awareness and action.
#WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung
Early detection saves lives. Let’s keep pushing for awareness and action.
#WorldLungCancerDay #EarlyDetection #LungCancerAwareness #CyPathLung
“CyPath® Lung gave us the clarity we needed to act early,” said Dr. Gordon Downie, CMO, referring to a Stage 1A mucinous adenocarcinoma missed by other diagnostics.
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity
July 29, 2025 at 9:50 PM
“CyPath® Lung gave us the clarity we needed to act early,” said Dr. Gordon Downie, CMO, referring to a Stage 1A mucinous adenocarcinoma missed by other diagnostics.
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity
Every early diagnosis is a life potentially saved.
Read the press release: bit.ly/4l6uOvn
#CyPathLung #LungCancer #bioAffinity
New case study: noninvasive CyPath® Lung detected a Stage 1A neuroendocrine tumor that PET, bronchoscopy & serum markers missed, leading to timely surgical removal.
Noninvasive. Precise. Life saving.
Full PR: bit.ly/44MjPCz
#LungCancer #EarlyDetection #CyPathLung #PhysicianHighlights
Noninvasive. Precise. Life saving.
Full PR: bit.ly/44MjPCz
#LungCancer #EarlyDetection #CyPathLung #PhysicianHighlights
July 24, 2025 at 11:01 PM
New case study: noninvasive CyPath® Lung detected a Stage 1A neuroendocrine tumor that PET, bronchoscopy & serum markers missed, leading to timely surgical removal.
Noninvasive. Precise. Life saving.
Full PR: bit.ly/44MjPCz
#LungCancer #EarlyDetection #CyPathLung #PhysicianHighlights
Noninvasive. Precise. Life saving.
Full PR: bit.ly/44MjPCz
#LungCancer #EarlyDetection #CyPathLung #PhysicianHighlights
Canada awards patent for CyPath® Lung, expanding global protection of our noninvasive test for early lung cancer detection. With 92% sensitivity and 88% accuracy, early diagnosis can save lives. PR: bit.ly/CanadaPatent
#CyPathLung #LungCancer #Diagnostics #Biotech #Canada
#CyPathLung #LungCancer #Diagnostics #Biotech #Canada
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic - bioAffinity
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechn...
bit.ly
July 22, 2025 at 5:53 PM
Canada awards patent for CyPath® Lung, expanding global protection of our noninvasive test for early lung cancer detection. With 92% sensitivity and 88% accuracy, early diagnosis can save lives. PR: bit.ly/CanadaPatent
#CyPathLung #LungCancer #Diagnostics #Biotech #Canada
#CyPathLung #LungCancer #Diagnostics #Biotech #Canada
CyPath® Lung gives physicians timely, actionable insights for patients at risk of lung cancer. Early detection is critical and fast results save lives.
Noninvasive. Accurate Results.
See how Dr. Nadarajah uses CyPath® Lung: bit.ly/DrNadarajah
#CyPathLung #LungCancer #PhysicianHighlights
Noninvasive. Accurate Results.
See how Dr. Nadarajah uses CyPath® Lung: bit.ly/DrNadarajah
#CyPathLung #LungCancer #PhysicianHighlights
July 17, 2025 at 2:59 PM
CyPath® Lung gives physicians timely, actionable insights for patients at risk of lung cancer. Early detection is critical and fast results save lives.
Noninvasive. Accurate Results.
See how Dr. Nadarajah uses CyPath® Lung: bit.ly/DrNadarajah
#CyPathLung #LungCancer #PhysicianHighlights
Noninvasive. Accurate Results.
See how Dr. Nadarajah uses CyPath® Lung: bit.ly/DrNadarajah
#CyPathLung #LungCancer #PhysicianHighlights
“Securing this IP positions us well for future opportunities in one of the world’s largest and most underserved healthcare markets.”
Maria Zannes, President & CEO
CyPath® Lung has shown 92% sensitivity, 87% specificity
Read the PR: bit.ly/3IuVgS3
#LungCancer #Innovation #EarlyDetection
Maria Zannes, President & CEO
CyPath® Lung has shown 92% sensitivity, 87% specificity
Read the PR: bit.ly/3IuVgS3
#LungCancer #Innovation #EarlyDetection
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic - bioAffinity
One third of world’s smokers live in China, which has highest rate of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advanc...
bit.ly
July 15, 2025 at 4:59 PM
“Securing this IP positions us well for future opportunities in one of the world’s largest and most underserved healthcare markets.”
Maria Zannes, President & CEO
CyPath® Lung has shown 92% sensitivity, 87% specificity
Read the PR: bit.ly/3IuVgS3
#LungCancer #Innovation #EarlyDetection
Maria Zannes, President & CEO
CyPath® Lung has shown 92% sensitivity, 87% specificity
Read the PR: bit.ly/3IuVgS3
#LungCancer #Innovation #EarlyDetection